NEW YORK, September 23, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on the following equities: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Arrowhead Research Corporation (NASDAQ: ARWR), Advaxis, Inc. (NASDAQ: ADXS), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), Array BioPharma Inc. (NASDAQ: ARRY). On Tuesday, September 22, 2015, NASDAQ ended at 4,756.72, down 1.50%, DJIA declined 1.09% to finish the day at 16,330.47, and the S&P closed at 1,942.74, down 1.23%. Register for your complimentary reports at the links given below.  

--

Alexion Pharmaceuticals Inc.  

--

Alexion Pharmaceuticals Inc.'s stock edged lower by 0.79% to close Tuesday's session at USD 159.24. The company's shares oscillated between USD 156.00 and USD 159.79. The stock recorded a trading volume of 2.25 million shares, which was above its 50-day daily average volume of 1.68 million shares and above its 52-week average volume of 1.56 million shares. Over the last three days Alexion Pharmaceuticals Inc.'s shares have declined by 5.21%. Furthermore, over the last three months the stock has lost 16.59% and in the past six months the shares have shed 13.19%. On a compounded total return basis, the company stock has generated negative returns of 5.79% in the past one week and 8.38% in the past one month. Further, the company is trading at a price to earnings ratio of 54.53 and price to book ratio of 4.21. Sign up and read the free notes on ALXN at: http://www.aciassociation.com/ALXN.pdf

--

Arrowhead Research Corp  

--

The stock of Arrowhead Research Corp lost 4.86% to close Tuesday's session at USD 7.05. The shares of the company moved in the range of USD 6.87 and USD 7.61 in trade during the day. A trading volume of 2.21 million shares was recorded, which was greater than its 150-day daily average volume of 1.35 million shares. Over the last five days Arrowhead Research Corp's shares have advanced 0.71% and in the past one month the stock has gained a momentum of 27.03%. Additionally, over the last three months the stock has declined 5.24% and in the past six months the shares have registered a loss of 1.54%. The stock is trading at a price to book ratio of 3.19 while the historical PB ratio is close to 4.85. Register for free on ACI Association and access the latest research on ARWR at: http://www.aciassociation.com/ARWR.pdf

--

Advaxis Inc.  

--

Advaxis Inc.'s stock increased by 0.81% to close Tuesday's session at USD 16.12. The company's shares fluctuated in the range of USD 15.68 and USD 17.04. A total of 1.99 million shares exchanged hands, which surpassed its 50-day daily average volume of 1.19 million shares and was above its 52-week average volume of 1.22 million shares. Over the last three days Advaxis Inc.'s shares have declined by 18.21% and in the past one week the stock has moved down 17.12%. The company stock has shown a negative return of 22.76% in the past three months and a positive return of 28.55% in the last half year, on a compounded total return basis. The complete research on ADXS is available for free at: http://www.aciassociation.com/ADXS.pdf

--

Allscripts Healthcare Solutions Inc.  

--

Allscripts Healthcare Solutions Inc.'s stock slipped by 2.03% to close Tuesday's session at USD 13.55. The company's shares oscillated between USD 13.45 and USD 13.73 in trade during the day. The stock recorded a trading volume of 1.93 million shares, which was below its 50-day daily average volume of 3.18 million shares and below its 52-week average volume of 2.99 million shares. Over the last five days Allscripts Healthcare Solutions Inc.'s shares have declined by 0.70% and in the past one month the stock has lost 1.63%. In addition, over the last three months the stock has lost 6.07% and year to date the shares have picked up 6.07%. The stock is trading at a price to book ratio of 1.85 and price to sales ratio of 1.86. Free in-depth research on MDRX is available at:  http://www.aciassociation.com/MDRX.pdf

--

Array Biopharma Inc.  

--

Array Biopharma Inc.'s stock declined 3.36% to close Tuesday's session at USD 5.18. The share price vacillated between USD 5.10 and USD 5.33. The stock recorded a trading volume of 1.87 million shares, which was above its 50-day daily average volume of 1.70 million shares and below its 52-week average volume of 2.17 million shares. Over the last three days Array Biopharma Inc.'s shares have declined by 12.35% and in the past one week the stock has moved down 12.20%. Moreover, in the last six months the stock has lost 34.01% and year to date the shares have picked up 9.51%. Further, the company is trading at a price to earnings ratio of 518.00 and price to book ratio of 17.26. Additionally, the stock is trading at a price to sales ratio of 14.20. The complimentary notes on ARRY can be downloaded in PDF format at:  http://www.aciassociation.com/ARRY.pdf

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.  

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE www.aciassociation.com

Copyright 2015 PR Newswire

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arrowhead Pharmaceuticals Charts.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arrowhead Pharmaceuticals Charts.